Abstract
Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and interactions as well as restricted, repetitive behaviors and interests. Pharmacologic interventions are often needed to manage irritability, aggressive behaviors and hyperactivity. Pharmacogenomic studies have investigated genetic associations with treatment response and side effects in an attempt to better understand drug mechanisms in hopes of optimizing the balance of symptom improvement versus side effects. The majority of pharmacogenomic studies to date have focused on antipsychotics, antidepressants and stimulants that are the most commonly utilized medication classes for ASD. This review is a comprehensive examination of the existing pharmacogenomic studies in ASD highlighting the current state of knowledge regarding genetic variation influencing pharmacokinetics and pharmacodynamics, and associated clinical outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 403-414 |
| Number of pages | 12 |
| Journal | Pharmacogenomics |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Mar 2017 |
Bibliographical note
Funding Information:This work was funded by NIH grants HD055751 (EH Cook) and MH083888 (JR Bishop). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2017 Future Medicine Ltd.
Keywords
- autism spectrum disorder
- escitalopram
- fluvoxamine
- methylphenidate
- pharmacogenetics
- pharmacogenomics
- risperidone